Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review, H2 2017 – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Chronic
Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review,
H2 2017”
report has been added to Research and Markets’
offering.

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline
Review, H2 2017, provides comprehensive information on the therapeutics
under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid
Leukemia) (Oncology), complete with analysis by stage of development,
drug target, mechanism of action (MoA), route of administration (RoA)
and molecule type. The guide covers the descriptive pharmacological
action of the therapeutics, its complete research and development
history and latest news and press releases.

The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
(Oncology) pipeline guide also reviews of key players involved in
therapeutic development for Chronic Myelocytic Leukemia (CML, Chronic
Myeloid Leukemia) and features dormant and discontinued projects. The
guide covers therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Pre-Registration,
Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5,
27, 30, 22 and 5 respectively. Similarly, the Universities portfolio in
Phase II, Phase I, Preclinical and Discovery stages comprises 6, 4, 7
and 3 molecules, respectively.

Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology)
pipeline guide helps in identifying and tracking emerging players in the
market and their portfolios, enhances decision making capabilities and
helps to create effective counter strategies to gain competitive
advantage.

Key Topics Covered:

  1. Introduction
  2. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Overview
  3. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) –
    Therapeutics Development
  4. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) –
    Therapeutics Assessment
  5. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) –
    Companies Involved in Therapeutics Development
  6. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drug
    Profiles
  7. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Dormant
    Projects
  8. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) –
    Discontinued Products
  9. Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Product
    Development Milestones
  10. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/59c7vr/chronic?w=4

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Leukemia
Drugs